Astellas Pharma Inc. (TSE: 4503), a Japan-based pharmaceutical company, and Graduate School of Medicine / Faculty of Medicine, Osaka University announced on Monday that the company's wholly owned subsidiary Astellas Institute for Regenerative Medicine (AIRM), Universal Cells, a wholly owned subsidiary of Astellas, and Osaka University have signed a research collaboration agreement to develop innovative pluripotent stem cell-derived cartilage organoid cell therapy intended for the treatment of intervertebral disc degenerative disease.
Universal Cells holds the rights to Universal Donor Cell (UDC) technology to create cell therapy products from pluripotent stem cells that have reduced risk of immune rejection by genetically modifying Human Leukocyte Antigen (HLA) using gene editing technology.
Under the terms of the agreement, the three parties aim to combine the cartilage tissue creation protocol established by Professor Noriyuki Tsumaki of (Graduate School of Frontier Biosciences / Premium Research Institute for Human Metaverse Medicine) the Department of Tissue Biochemistry and Molecular Biology, Graduate School of Medicine, Osaka University University, a researcher in cartilage diseases, Universal Cells' UDC technology, and AIRM's exceptional R&D expertise in cell therapy, and jointly create an innovative cell therapy for intervertebral disc degenerative disease.
Yoshitsugu Shitaka, PhD, Astellas chief scientific officer (CScO), said,
'Astellas is committed to achieving our VISION of being 'on the forefront of healthcare change, turning innovative science into VALUE for patients'. We hope to provide our cutting-edge UDC technology to academia and startups globally, and deliver next-generation cell therapies to patients. This partnership is an important step in the open innovation using UDC technology.'
Galmed reveals novel pharmacodynamic blood markers for Aramchol SCD1 inhibitor
Evommune initiates EVO756 Phase 2b trial in adults with chronic spontaneous urticaria
Telix Pharmaceuticals' TLX101 glioma therapy candidate shows promising efficacy
FluoGuide begins phase II trial of FG001 for head and neck cancer
Sanofi advances respiratory pipeline with positive amlitelimab data and expanded clinical programmes
PRISM BioLab agrees drug discovery collaboration with Elix
Sumitomo Pharma America signs research and development agreement with NCI
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Genflow Biosciences enters into AI-driven research agreement with Heureka Labs
Sichuan Kelun-Biotech reveals sacituzumab tirumotecan (sac-TMT) clinical studies results
Kyowa Kirin completes construction of new Drug Substance manufacturing facility
Amgen's IMDELLTRA shows superior overall survival in small cell lung cancer trial
OncoZenge AB signs licensing deal with Avernus Pharma for BupiZenge in GCC region